GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Silk Road Medical Inc (NAS:SILK) » Definitions » Piotroski F-Score

Silk Road Medical (Silk Road Medical) Piotroski F-Score : 5 (As of May. 14, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Silk Road Medical Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Silk Road Medical has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Silk Road Medical's Piotroski F-Score or its related term are showing as below:

SILK' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 5

During the past 7 years, the highest Piotroski F-Score of Silk Road Medical was 5. The lowest was 2. And the median was 4.


Silk Road Medical Piotroski F-Score Historical Data

The historical data trend for Silk Road Medical's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silk Road Medical Piotroski F-Score Chart

Silk Road Medical Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial 5.00 4.00 5.00 3.00 3.00

Silk Road Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 5.00 5.00 3.00 5.00

Competitive Comparison of Silk Road Medical's Piotroski F-Score

For the Medical Devices subindustry, Silk Road Medical's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silk Road Medical's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Silk Road Medical's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was -13.484 + -12.788 + -13.011 + -14.136 = $-53.4 Mil.
Cash Flow from Operations was -4.616 + -6.798 + -8.453 + -15.322 = $-35.2 Mil.
Revenue was 45.298 + 44.435 + 47.27 + 48.484 = $185.5 Mil.
Gross Profit was 32.294 + 32.385 + 34.802 + 36.501 = $136.0 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(259.587 + 263.36 + 260.864 + 265.309 + 252.314) / 5 = $260.2868 Mil.
Total Assets at the begining of this year (Mar23) was $259.6 Mil.
Long-Term Debt & Capital Lease Obligation was $75.9 Mil.
Total Current Assets was $235.7 Mil.
Total Current Liabilities was $21.3 Mil.
Net Income was -15.398 + -10.319 + -12.614 + -16.46 = $-54.8 Mil.

Revenue was 33.173 + 37.374 + 40.071 + 40.131 = $150.7 Mil.
Gross Profit was 24.161 + 28.066 + 29.092 + 27.605 = $108.9 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(143 + 162.721 + 162.544 + 269.685 + 259.587) / 5 = $199.5074 Mil.
Total Assets at the begining of last year (Mar22) was $143.0 Mil.
Long-Term Debt & Capital Lease Obligation was $74.8 Mil.
Total Current Assets was $230.3 Mil.
Total Current Liabilities was $20.9 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Silk Road Medical's current Net Income (TTM) was -53.4. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Silk Road Medical's current Cash Flow from Operations (TTM) was -35.2. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=-53.419/259.587
=-0.20578457

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-54.791/143
=-0.38315385

Silk Road Medical's return on assets of this year was -0.20578457. Silk Road Medical's return on assets of last year was -0.38315385. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Silk Road Medical's current Net Income (TTM) was -53.4. Silk Road Medical's current Cash Flow from Operations (TTM) was -35.2. ==> -35.2 > -53.4 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=75.886/260.2868
=0.29154763

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=74.848/199.5074
=0.37516403

Silk Road Medical's gearing of this year was 0.29154763. Silk Road Medical's gearing of last year was 0.37516403. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=235.694/21.337
=11.04625767

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=230.254/20.87
=11.03277432

Silk Road Medical's current ratio of this year was 11.04625767. Silk Road Medical's current ratio of last year was 11.03277432. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Silk Road Medical's number of shares in issue this year was 39.261. Silk Road Medical's number of shares in issue last year was 38.532. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=135.982/185.487
=0.73310798

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=108.924/150.749
=0.72255206

Silk Road Medical's gross margin of this year was 0.73310798. Silk Road Medical's gross margin of last year was 0.72255206. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=185.487/259.587
=0.71454657

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=150.749/143
=1.05418881

Silk Road Medical's asset turnover of this year was 0.71454657. Silk Road Medical's asset turnover of last year was 1.05418881. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+1+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Silk Road Medical has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Silk Road Medical  (NAS:SILK) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Silk Road Medical Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Silk Road Medical's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Silk Road Medical (Silk Road Medical) Business Description

Traded in Other Exchanges
Address
1213 Innsbruck Drive, Sunnyvale, CA, USA, 94089
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
Executives
Chas Mckhann director, officer: Chief Executive Officer 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Marie L. Jones officer: CAO and VP, Finance 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Lucas W. Buchanan officer: Chief Financial Officer C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Kevin M Klemz officer: EVP/Chief Legal Officer/Sec. 9600 54TH AVENUE NORTH, SUITE 100, PLYMOUTH MN 55442
Andrew S. Davis officer: Chief Commercial Officer C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Erica J. Rogers director, officer: President and CEO C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Richard Ruedy officer: EVP Clin & Reg. Affairs and QA C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Tony M. Chou director C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Tanisha Carino director C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Kevin J. Ballinger director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Rick D Anderson director 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Donald Zurbay director C/O ST. JUDE MEDICAL, INC., ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
Warburg Pincus Partners Gp Llc 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus & Co. 10 percent owner 450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147